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The mycobacterial cell envelope is crucial to host–pathogen
interactions as a barrier against antibiotics and the host immune
response. In addition, cell envelope lipids are mycobacterial vir-
ulence factors. Cell envelope lipid biosynthesis is the target of a
number of frontline tuberculosis treatments and has been the
focus of much research. However, the transport mechanisms by
which these lipids reach the mycomembrane remain poorly
understood. Many envelope lipids are exported from the cyto-
plasm to the periplasmic space via the mycobacterial membrane
protein large (MmpL) family of proteins. In other bacteria, lipo-
proteins can contribute to outer membrane biogenesis through
direct binding of substrates and/or protein–protein associa-
tions with extracytoplasmic biosynthetic enzymes. In this
report, we investigate whether the lipoprotein LpqN plays a
similar role in mycobacteria. Using a genetic two-hybrid
approach, we demonstrate that LpqN interacts with periplas-
mic loop domains of the MmpL3 and MmpL11 transporters
that export mycolic acid– containing cell envelope lipids. We
observe that LpqN also interacts with secreted cell envelope
biosynthetic enzymes such as Ag85A via pulldown assays.
The X-ray crystal structures of LpqN and LpqN bound to
dodecyl-trehalose suggest that LpqN directly binds trehalose
monomycolate, the MmpL3 and Ag85A substrate. Finally, we
observe altered lipid profiles of the lpqN mutant during bio-
film maturation, pointing toward a possible physiological
role for the protein. The results of this study suggest that
LpqN may act as a membrane fusion protein, connecting
MmpL transporters with periplasmic proteins, and provide
general insight into the role of lipoproteins in Mycobacte-
rium tuberculosis cell envelope biogenesis.
Mycobacterium tuberculosis (Mtb)2 is the causative agent of
the human disease tuberculosis (TB). TB is one of the most
devastating human diseases, and it remains a major public
health concern. In 2017, there were 10 million new cases and
1.3 million deaths caused by TB (1). The cell envelope of Mtb is
a waxy, lipid-rich structure that acts as a robust physical barrier
to host antimicrobial defenses and antibiotics. This intrinsic
resistance is largely conferred by mycolic acids, extremely long
chain (C60 –90) -alkyl--hydroxy fatty acids that are major
constituents of the mycobacterial cell envelope (2). Mycolic
acids and their derivatives form an outer layer analogous to
the outer membrane of Gram-negative bacteria, termed the
mycomembrane. The mycomembrane consists of an inner leaf-
let of mycolylated arabinogalactan anchored to peptidoglycan
(the mAGP complex) and an outer leaflet of predominantly
mycolylated free lipids (3, 4). In addition to acting as a passive
physical barrier, certain cell envelope components can directly
interfere with host immune responses (5, 6). Therefore, the Mtb
cell envelope plays a crucial role at the host–pathogen interface
to promote bacterial survival.
The biogenesis of the mycobacterial cell envelope is complex
and incompletely described. One class of proteins involved in
transport of cell envelope components is the mycobacterial
membrane protein large (MmpL) family. The MmpLs are poly-
topic membrane proteins that mediate transport of large
hydrophobic substrates from the cytoplasm of the bacterium to
the periplasmic space, where they are subsequently incorpo-
rated into the cell envelope (7–9). The MmpLs are considered
members of the resistance–nodulation– cell division (RND)
superfamily of membrane transporters that typically couple the
proton motive force to export of their substrates (10, 11). A
subset of MmpLs (MmpL1/2/4/5) are accompanied in the
genome by genes encoding mycobacterial membrane protein
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small (MmpS) proteins (12) that are predicted to contain one or
two transmembrane segments and are likely involved in sub-
strate transport by their cognate MmpL protein.
The substrates of a number of MmpL transporters have been
identified. Of particular interest are those MmpL proteins that
transport mycolic acid– containing lipids. Most importantly,
MmpL3 (Rv0206c) transports trehalose monomycolate (TMM)
into the periplasmic space (13). There, mycolic acid transfer
catalyzed by members of the antigen 85 (Ag85) enzyme com-
plex generates the free lipid trehalose dimycolate (TDM) and
arabinogalactan-anchored mycolic acids, which together form
the mycomembrane (13–15). MmpL3 is therefore an essential
Mtb protein, because of the central role of mycolic acids in
mycobacterial physiology (16, 17). Another important MmpL
transporter is MmpL11 (Rv0202c), which we showed exports
species-specific mycolic acid– containing storage lipids such as
the mycolate wax ester and long-chain triacylglycerols in Mtb
and meromycolyl diacylglycerol in Mycobacterium smegmatis
(18, 19). These lipids are important for Mtb persistence,
because MmpL11-deficient Mtb exhibit attenuated survival
during in vitro and in vivo models of infection and in an in vitro
model of dormancy (10, 19).
Many of the insights into MmpL transporter function have
been gleaned from comparison with other protein members of
the larger RND transporter superfamily. RND superfamily pro-
teins are primarily associated with antibiotic resistance and
stress response in Gram-negative bacteria (reviewed in Ref. 20).
They typically function in concert with a membrane fusion pro-
tein (MFP) and an outer membrane factor to form a tripartite
export apparatus that extrudes substrates through the periplasm
directly to the extracellular environment (21–25). Although Mtb
exhibits pseudo–Gram-negative membrane organization, it
remains to be determined whether the MmpLs interact with
periplasmic and outer membrane proteins to form a similar tripar-
tite pump that would enable efficient translocation and proper
localization of their substrates. Some secreted lipoproteins
direct the proper localization of virulence-associated lipids
within the cell envelope, suggesting that these proteins may be
functioning as MFPs in Mtb. Notably, translocation of phthio-
cerol dimycocerosate (PDIM) to the mycomembrane depends
on the lipoprotein LppX, presumably through direct binding of
PDIM by LppX (26). Similarly, the lipoprotein LprG binds both
the virulence-associated glycolipid lipoarabinomannan and
triacylglycerides and is required for translocation of these sub-
strates to the cell envelope (27). Furthermore, LprG interacts
with the Ag85A mycolyltransferase, implicating this lipopro-
tein in the transmycolylation processes that generate the
mycomembrane (28). The MmpS proteins are also candidate
MFPs, given that MmpS4/5 interact with their cognate
MmpL4/5 partners and are required for transport of their sid-
erophore substrates (29). However, only a minority of MmpL
transporters have cognate MmpS proteins (MmpS1/2/4/5), and
MmpL-MmpS protein–protein interactions have not been
demonstrated for MmpS1/2. This raises the possibility that
there are unidentified Mtb proteins that function as quasi-
MFPs to assist in delivering MmpL-transported lipids through
the periplasm to their cell envelope destinations.
We sought to identify proteins that might function as MFPs
with MmpL3 and MmpL11. Using genetic methods, we identi-
fied the secreted lipoprotein LpqN (Rv0583c) as a periplasmic
interacting partner of both MmpL3 and MmpL11. Biochemical
and genetic studies suggested that LpqN may also associate
with members of the Ag85 enzyme complex and plays a role in
cell envelope lipid changes during biofilm maturation. These
results suggest that LpqN may function as an MFP of MmpL3/
11. This model is supported by the crystal structures of apo- and
lipid-bound LpqN reported herein.
Results
LpqN interacts with D2 loops of mycolate lipid transporters
MmpL3 and MmpL11
MmpL3 and MmpL11 are structurally similar and catego-
rized into the hydrophobe/amphiphile efflux 3 (HAE3) subfam-
ily of the larger RND transporter superfamily (29, 30). They
possess two periplasmic loop domains, termed D1 and D2, as
well as a cytosolic C-terminal domain (31). The D1, D2, and
C-terminal domains are therefore the most likely regions of
interaction between MmpL11 and biosynthetic enzymes or
other transport machinery. To identify periplasmic proteins
that interact with MmpL11TB, we used the mycobacterial pro-
tein fragment complementation (M-PFC) system (32). In this
two-hybrid system, the “bait” and “prey” are expressed indepen-
dently as fusion proteins with two fragments of the murine
dihydrofolate reductase (DHFR [F1,2] and DHFR [F3]). Func-
tional reconstitution by two interacting mycobacterial proteins
when expressed in M. smegmatis results in trimethoprim resis-
tance. Integrative plasmids were constructed containing D1
and D2 domains in-frame with the DHFR [F3] fragment and
then transformed into M. smegmatis to generate a bait strain.
An H37Rv Mtb prey library of over 106 independent clones was
generated in pUAB300. Clones encoding putative proteins that
interact with MmpL11TB were obtained by transforming the
library constructs into the M. smegmatis bait strain and select-
ing for trimethoprim resistance. Ultimately, no positive clones
were identified using the D1 domain. Using the D2 construct,
we isolated two independent clones that contained a DHFR
[F1,2]–LpqN fusion. LpqN was the only positive clone identi-
fied using the MmpL11 D2 domain as bait. This suggests that
LpqN (Rv0583c) interacts with the periplasmic D2 domain of
MmpL11TB.
MmpL11 and MmpL3 are topologically similar conserved
transporters of mycolic acid– containing lipids. Therefore, we
theorized that LpqN might interact with the periplasmic
domains of MmpL3 as well. To address this and validate our
initial M-PFC screen, we assessed the interactions between the
MmpL3 and MmpL11 periplasmic D1 and D2 loops with LpqN
using a directly cloned (nonlibrary) LpqN prey construct, which
contained the soluble domain of LpqN fused to DHFR [F1,2].
We found that the D2, but not the D1, loops of both MmpL3
and MmpL11 conferred trimethoprim resistance when co-ex-
pressed with LpqN (Table 1). These results suggest that LpqN
interacts with the D2 periplasmic regions of both MmpL3 and
MmpL11.
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To verify the interaction between LpqN and MmpL11 in vivo,
we heterologously expressed affinity-tagged Mtb protein in
M. smegmatis. Although both proteins were successfully ex-
pressed, we were unfortunately unable to co-purify LpqN with
MmpL11 in the absence or presence of cross-linking (Fig. S1).
LpqN interacts with cell envelope lipid biosynthetic enzymes
We hypothesized that LpqN might act as an adaptor protein
in the periplasm to facilitate interactions between MmpL pro-
teins and periplasmic proteins. To identify secreted interacting
partners of LpqN, we performed a pulldown purification of
affinity-tagged LpqN incubated with Mtb culture filtrate pro-
teins (CFPs) in the presence/absence of formaldehyde as a pro-
tein cross-linking reagent. Interacting proteins were subse-
quently identified via MS and categorized as weak or strong
LpqN-interacting partners based on whether or not protein cross-
linking was required for co-purification (Table 2). As a control, we
analyzed the background binding of CFP to the metal affinity resin.
Intriguingly, secreted cell envelope biosynthetic enzymes, such as
the mycolyltransferase Ag85A and the mycocerosic acid synthase
Mas, were enriched in the LpqN co-purified samples relative to
background. Ag85B also copurified with LpqN, although to a
lesser degree. Ag85 and Mas enzymes are responsible for the
biosynthesis of the cell envelope lipids TDM and PDIM, respec-
tively. These data suggest that LpqN interacts with periplasmic cell
envelope biosynthetic enzymes.
The possible interaction between Ag85A and LpqN was
interesting, given the key role that the Ag85 complex plays in
the biogenesis of the mycobacterial cell envelope. Furthermore,
the primary substrate of the Ag85 enzymes is TMM, which
is exported by MmpL3. Attempts to demonstrate a direct inter-
action between LpqN and Ag85A using a heterologous dual-
expression M. smegmatis co-immunopurification strategy
were unsuccessful (Fig. S2). However, there is precedent for
interactions between lipoproteins and members of the Ag85
complex, as evidenced by the recently reported LprG–Ag85A
interaction (28). LprG (Rv1411c) binds phosphatidylinositol-
containing glycolipids rather than mycolic acids (33). Never-
theless, LprG appears to contribute to mycolylation of cell wall
analogues (28). We performed head-to-head M-PFC assays to
determine whether the MmpL3 or MmpL11 D2 domains are
capable of interacting with other LpqN family members (LpqT,
Mtc28) or LprG. LpqT and Mtc28 also interact with the
MmpL11 D2 domain, but not the MmpL3 D2 domain, via
M-PFC (Table S1). The structurally distinct LprG protein also
interacted with the MmpL11, but not MmpL3, D2 domain via
M-PFC. These results suggest the possibility that multiple lipo-
proteins act as adaptors for the MmpL transporters.
LpqN contributes to Mtb biofilm lipid composition
MmpL3 transports TMM, which is essential for replication,
whereas MmpL11 transports cell envelope lipids that are
important for biofilm formation. To investigate a possible role
for LpqN in mycobacterial cell envelope biogenesis, we gener-
ated an lpqN-deletion mutant in H37Rv Mtb (lpqN) via allelic
exchange (Fig. S3, A and B). There was not a growth defect in
either 7H9 or Sauton’s medium (Fig. S3, C and D). We then
characterized Mtb WT, lpqN, and complemented strain cell
envelope lipids from bacteria grown planktonically and in biofilms
by TLC. We did not observe any differences in TMM and TDM
levels between the WT, mutant, or complemented mutant (Mtb
lpqN::lpqN) lipid profiles using the chloroform:methanol:am-
monium hydroxide (80:20:2) solvent system (Fig. 1, A and B). We
also analyzed the mycolic acid methyl esters of mAGP, which did
not differ significantly between strains (Fig. 1C). Consistent with
these results, we also did not see significant differences in the
LC/MS profiles among the lipid extracts, in particular, of TMM
and TDM (Figs. S4 and S5). This was not surprising because the
lpqN mutant did not possess a growth defect.
Our analyses of Mtb biofilms over time indicate that the lipid
profiles shift as the biofilm matures. Although there were no
differences between WT and lpqN mutant lipids at 3 weeks
(Fig. 1D), we noted the relative accumulation of an apolar lipid
in the lpqN mutant samples that ran with a similar Rf to the wax
ester standard in 4 weeks (Fig. 1E, asterisk). We speculated that
the apolar lipid (Fig. 1E, asterisk) in the mutant was a wax ester.
However, mass spectrometric analysis of the extract of this apolar
TLC spot did not yield mass spectra that directly identified any
known mycobacterial lipids. These results countered our assump-
tion that the spot is wax ester and are consistent with HPLC/MS
results that showed no difference in wax ester between WT and
LpqN (Fig. S4E). The lpqN mutant biofilm also appeared to accu-
mulate a less-apolar band that was similarly recalcitrant to identi-
fication (Fig. 1E, asterisks). Together, these biofilm lipid profiles
suggest that LpqN may contribute to cell envelope lipid turnover
or remodeling during biofilm development.
The LpqN crystal structure suggests that LpqN may directly
bind lipids
To gain additional insight into LpqN function, the crystal
structure of apo-LpqN was determined at a resolution of 1.65 Å
using single anomalous dispersion (Table 3 and Fig. 2). Because
LpqN might play a role in cell envelope biogenesis, we also
determined structures of LpqN in complexes with dodecyl tre-
halose (6LT) and trehalose 6-decanoate (T6D) to resolutions of
1.37 and 1.74 Å, respectively. We resolved these two ligand-
bound LpqN structures by using molecular replacement and
utilizing the apo-LpqN structure as a search model (Table 3 and
Fig. 2). Both 6LT and T6D are water-soluble compounds that
are structurally similar to the insoluble lipid molecule TMM in
that they contain a two-ring system of the trehalose moiety.
Therefore, 6LT and T6D are ideal compounds to mimic TMM
Table 1
M-PFC assessed via trimethoprim minimal inhibitory concentrations
of MmpL3/11TB D1 and D2 domain–LpqN interactions
MIC, minimal inhibitory concentration.
Insert in
pUAB200 Insert in pUAB300
Trim MIC
(g/ml)
— Rv2763 (dfr) positive control 200
— LpqN 6.25
MmpL3 D1 — 6.25
MmpL3 D1 LpqN 6.25
MmpL11 D1 — 6.25
MmpL11 D1 LpqN 6.25
MmpL3 D2 — 6.25
MmpL3 D2 LpqN 100
MmpL11 D2 — 6.25
MmpL11 D2 LpqN 50
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with respect to the interaction with LpqN. The crystals of apo-
LpqN, LpqN– 6LT, and LpqN–T6D took the space groups
C121, I4, and I4, respectively. A single molecule of LpqN was
found in the asymmetric unit of each crystal. The molecule of
LpqN consists of three -helices and seven -strands. These
helices and strands are designated numerically from the N to C
termini: 1 (61– 68), 1 (84 – 86), 2 (104 –108), 3 (120 –124),
2 (134 –147), 4 (170 –176), 5 (179 –182), 6 (184 –192), 7
(195–206), and 3 (210 –222). Based on the orientation of apo-
LpqN within the asymmetric unit, the dimensions of this pro-
tein can be measured to be 45 Å  40 Å  35 Å. Accordingly,
4, 5, 6, 7, and 3 are involved in forming a shallow cavity,
presumably constituting a ligand binding site. The interior wall
of this cavity consists mainly of hydrophobic and polar residues
including Leu-87, Ile-121, Val-183, Ala-184, Leu-201, Ala-203,
and Met-214.
Superimposition of the structures of apo-LpqN and LpqN–
6LT results in an overall root-mean-square deviation (RMSD)
of 0.8 Å, suggesting that these two structures are similar in
conformation. However, detailed inspection indicates that the
two structures are quite different. The main difference between
the two conformations is the shift in location of 3 and the
rearrangement of the secondary structures of several random
loops located at the 6LT-binding site. These loops, including
residues 93–96, 158 –160, and 167–170, convert into  strands
after binding 6LT. These changes result in a larger internal
cavity for LpqN– 6LT compared with that of apo-LpqN. In
addition, a specific deep binding pocket, which was not
observed in apo-LpqN, was found in LpqN– 6LT to coordinate
with the binding of the carbon chain of the 6LT ligand. Because
the secondary structure of LpqN– 6LT is very different, we
reassigned its structural features to facilitate the description of
this ligand-bound protein. The secondary structure assign-
ments of 6LT-bound LpqN from the N to C termini are: 1
(61– 67), 1 (93–96), 2 (104 –109), 2 (134 –147), 3 (158 –
160), 4 (167–176), 5 (179 –185), 6 (187–192), 7 (195–
206), and 3 (210 –223).
In the structure of LpqN– 6LT, the 6LT molecule is bound
within the cavity surrounded by 4, 5, 7, and 3. The dodecyl
tail of 6LT is completely buried inside the LpqN protein, leaving
its two sugar rings of the trehalose head group partially exposed
to solvent. Within 6 Å of the dodecyl group of 6LT, 12 amino
acids contact and secure the hydrocarbon tail (Fig. 3). Although
the trehalose moiety of 6LT only partially contacts the LpqN
protein, the binding of this two-ring head group is extensive.
Ser-173 of LpqN forms a hydrogen bond with the trehalose
head group to anchor this ligand. Gly-153 also donates its back-
bone oxygen to make another hydrogen bond with the treha-
lose moiety. Ser-154 and Gly-171 also participate in binding
this head group. In addition, Gln-152 is 3.7 Å from the trehalose
head group and interacts with the ligand via electrostatic
interaction.
The structure of LpqN–T6D resembles that of LpqN– 6LT.
Superimposition of these two structures leads to an RMSD of
Table 2








Rv0583c  lipoprotein lpqN 54 1862 1774
Rv2220  glutamine synthetase glnA1 15 54 121
Rv3804c  fibronectin-binding protein antigen fbpA, Ag85A 18 35 100
Rv1908c  catalase-peroxidase-peroxynitritase T katG 22 46 83
Rv2780  secreted L-alanine dehydrogenase ald 11 32 76
Rv1475c  aconitate hydratase A acn 3 25 60
Rv1980c  immunogenic protein mpt64 16 21 20
Rv0350  chaperone protein dnaK 50 60 51
Rv0896  citrate synthase I gltA2 3 2 57
Rv006c  isocitrate dehydrogenase icd2 0 0 33
Rv3248c  adenosylhomocysteinase sahH 4 4 49
Rv0440  60-kDa chaperonin groEL2 9.818 15.6 18.947
Rv1098c  fumarate hydratase fumC 8 8 20
Rv0211  phosphoenolpyruvate carboxykinase pckA 4 6 26
Rv2940c  mycocerosic acid synthase mas 0 3 27
Rv0363c  fructose-bisphosphate aldolase fba 2 11 23
Rv2467  aminopeptidase N pepN 2 5 23
Rv3418  10-kDa chaperonin groS 7 4 22
Rv2030c  uncharacterized protein 1 8 21
Rv0462  dihydrolipoamide dehydrogenase lpd 0 2 20
Rv1017c  ribose-phosphate pyrophosphokinase prsA 7 13 20
Rv1074c  acetyl-CoA acetyltransferase fadA3 0 3 20
Rv1886c  secreted fibronectin-binding protein fbpB, Ag85B 0 3 19
Rv1093  serine hydroxymethyltransferase 1 glyA1 3 6 19
Rv2244  meromycolate extension acyl carrier protein acpM 14 13 18
Rv2031c  -crystallin hspX 1 4 17
Rv0315  probable -1,3-glucanase precursor 0 0 12
Rv2146c  N-acetyltransferase eis 0 4 11
Rv1837c  malate synthase G glcB 0 0 7
Rv0934  periplasmic phosphate-binding lipoprotein pstS1 0 1 6
Rv0379  protein transport protein secE2 2 0 5
Rv1860  alanine and proline rich secreted protein apa 2 0 5
Rv1392  S-adenosylmethionine synthetase metK 0 0 5
Rv0164  conserved hypothetical protein TB18.5 0 0 4
Rv1448c  transaldolase tal 0 0 4
Rv1449c  transketolase tkt 0 0 4
Rv3628  inorganic pyrophosphatase ppa 0 0 4
aCell values are the summed spectral counts of identified peptides corresponding to the indicated protein, from three biological replicate experiments.
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0.1 Å, suggesting that these two structures are almost identical.
Again, the main difference between the conformation of these
two structures is the switch of local secondary structures from
random loops to  strands. For example, residues 70 –74,
84 – 86, 120 –129, 160 –162, 165–167, 185–187, and 225–227
are found to form flexible loops in the structure of LpqN– 6LT.
These residues are all incorporated into different  strands.
Based on these structures, it appears that the LpqN protein is
able to easily switch its secondary structures to accommodate
for substrate binding. As a result, the LpqN– 6LT forms three
-helices and nine -strands: 1 (61– 67), 1 (70 –74), 2 (84 –
86), 3 (93–96), 4 (104 –109), 5 (120 –129), 2 (134 –147),
6 (158 –162), 7 (165–176), 8 (179 –192), 9 (195–206), 3
(210 –223), and 10 (225–227).
Like the binding of 6LT, the decanoate tail of T6D is com-
pletely buried in the binding cavity formed by LpqN. Within 6 Å
of this hydrocarbon chain, at least eight amino acids are actively
involved in anchoring the bound T6D. The trehalose head
group of T6D is partially exposed to solvent and is surrounded
by six amino acids. Ser-173 also participates by forming two
hydrogen bonds with the sugar-ring system of T6D to secure
the ligand (Fig. S4). The crystal structures of LpqN indeed sup-
Figure 1. LpqN contributes to biofilm lipid composition in late biofilm cultures. Mtb was grown in either complete 7H9 medium or Sauton’s medium
lacking Tween for planktonic and biofilm cultures, respectively. Mtb cell envelope surface lipids were harvested by hexanes extraction from planktonic culture
(A) or from biofilms harvested at 3 (B and D) or 4 (E) weeks and analyzed via TLC. mAGP was isolated from planktonic Mtb cell walls and MAMEs generated and
visualized by TLC (C). The solvent systems used for TLC were 80:20:2, v/v/v, CHCl3:MeOH:NH4OH (A and B); 99:5, v/v, hexanes:ethyl acetate (C); and 99:1, v/v,
toluene:acetone (D and E). TDM, TMM, triacylglycerol (TAG), and wax ester (WE) standards are indicated (Sigma). All TLCs were developed by charring in 10%
molybdophosphoric acid. In E, * and ** indicate species that accumulate in the lpqN mutant.
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port the idea that this lipoprotein is capable of binding cell
envelope lipids, such as TMM.
Discussion
Using genetic methods, we demonstrated that LpqN inter-
acts with the periplasmic D2 loop domains of the mycolate
transporters MmpL3 and MmpL11. As such, LpqN may act as
an MFP to facilitate substrate transport by MmpL3 and
MmpL11. The outcome of this interaction is likely proper mat-
uration of lipid substrates and/or the correct localization of
these lipids within the cell envelope. We hypothesize that LpqN
accomplishes these functions through direct binding of MmpL-
transported lipids, as our structural data suggest.
Several observations suggest that there is substantial redun-
dancy in this system. The cell envelope lipid profile of plank-
tonic and 3-week biofilm-grown Mtb lpqN mutant did not
differ from the WT, implying that the absence of LpqN does not
affect the cell envelope lipid composition during these growth
phases. Moreover, Mtb lpqN does not exhibit attenuated
growth in planktonic culture (Fig. S1C). Because mycolic acid
biosynthesis and MmpL3 are essential, we would expect that
perturbing mycolic acid incorporation within the cell envelope
would impact Mtb growth or viability. Given that lpqN-defi-
cient Mtb grows at a normal rate and has a normal cell envelope
lipid profile, LpqN is unlikely to be the sole facilitator of
periplasmic mycolic acid transport in Mtb. In support of this,
we note that the protein family to which LpqN belongs
(PF10738) contains other secreted Mtb proteins such as the
lipoprotein LpqT (Rv1016c) and the secreted proline-rich
Mtc28 (Rv0040c) (31).
Lipid binding may be a shared feature of the LpqN protein
family. The published structure of Mtc28 exhibits structural
homology to eukaryotic lipid-binding proteins such as CERT
and STARD13, as assessed by the DALI server (34 –37). Both
LpqT and Mtc28, as well as the unrelated lipoprotein LprG
(Rv1411c), interact with the MmpL11 D2 domain, but not the
MmpL3 D2 domain, via M-PFC (Table S1). Whether LpqT and
Mtc28 are capable of binding lipids is unknown, but LprG binds
phosphatidylinositol-containing glycolipids and interacts with
Ag85A (28, 33). Thus, there are presumably multiple intercon-
nected and redundant pathways of cell envelope biogenesis
operating in the periplasm that are mediated by lipoproteins
and other secreted proteins. Some periplasmic lipid mediators,
like LpqN, appear capable of interacting with both MmpL3
and MmpL11. Other potential mediators, like LpqT, Mtc28,
and LprG, appear to preferentially interact with MmpL11.
Although MmpL3 and MmpL11 both export mycolic acid–
containing lipids, MmpL3 is essential and therefore more cru-
cial to cell envelope physiology. Because lpqN-deficient Mtb is
physiologically unimpaired, there are likely additional MmpL3-
interacting periplasmic lipid mediators that remain to be iden-
tified. The recent characterization of the MmpL3-associated
protein TtfA in M. smegmatis supports the hypothesis that
MmpLs function in concert with accessory proteins to trans-
port their lipid substrates (38). LpqN and LpqN family proteins
Table 3
Data collection, phasing, and structural refinement statistics
apo-LpqN (6E5D) LpqN– 6LT (6E5F) LpqN–T6D (6MNA) SeMet–LpqN
Wavelength (Å) 0.9792 0.9792 0.9792 0.9792
Resolution (Å) 48.11–1.65 (1.71–1.65) 56.57–1.37 (1.41–1.37) 56.25–1.74 (1.85–1.74) 48.59–2.20 (2.32–2.20)
Unit cell parameters
a, b, c (Å) 99.3, 55.5, 44.6 80.0, 80.0, 59.2 79.5, 79.5, 60.0 99.0, 56.4, 44.5
, ,  (°) 90.0, 103.9, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 104.8, 90.0
Space group C121 I4 I4 C121
Total no. of reflections 187,144 334,562 337,062 155,435
Total no. of unique reflections 27,327 39,223 19,157 12,099
Wilson B factor (Å2) 24.2 20.73 27.5 42.6
Completeness (%) 96.1 (87.3) 99.7 (98.0) 99.3 (98.5) 99.6 (98.2)
Multiplicity 6.9 (5.3) 8.4 (3.2) 17.6 (17.6) 12.8 (13.3)
CC1/2 (%) 99.9 (95.6) 99.9 (64.5) 99.9 (64.3) 99.8 (98.2)
I/(I) 19.0 (2.9) 18.2 (1.9) 11.1 (1.5) 15.3 (5.1)
Phasing
No. of sites 2
Figure of merit 0.305
Refinement
Rwork (%)a 18.57 17.8 18.45
Rfree (%)b 20.85 20.35 21.75
No. of. atoms
Protein 2654 2661 2559
Water 140 107 101
Ligand 81 74
B factors (Å2)
Protein 35.17 30.96 34.88
Water 41.72 37.98 40.13
Ligand 70.05 69.63
RMSDs
Bond lengths (Å) 0.002 0.004 0.012
Bond angle (°) 0.545 0.764 1.242
Ramachandran plot (%)
Favored regions 96.84 98.14 100
Allowed regions 3.2 1.8 0
Outliers 0 0 0
aRwork  hkl Fobs 	 Fcalc/hklFobs.
bRfree was calculated as for Rwork but using 5% of the data that were excluded from the refinement calculation.
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are therefore likely redundant periplasmic mediators of lipid
transport.
Our work raises a number of questions regarding the func-
tion of LpqN. An M-PFC screen performed in M. smegmatis
initially identified LpqN as an interacting partner of MmpL11.
We also used this system to show LpqN interaction with
MmpL3. However, we were unable to demonstrate a direct bio-
chemical interaction between LpqN and MmpL11 when heter-
ologously co-expressed in M. smegmatis, suggesting a weak
interaction (Fig. S1). We also cannot exclude the possibility that
the LpqN–MmpL3/11 interaction is indirect and that some
putative mycobacterial adaptor protein or molecule is required
for LpqN to associate with these transporters. LpqN also
appeared to preferentially interact with Ag85A when incubated
with purified Mtb culture filtrate proteins. Similarly, we could
not successfully co-purify these two proteins when heterolo-
gously co-expressed in M. smegmatis (Fig. S2). Again, this may
reflect an indirect interaction with a species specific adaptor
protein. The observation that Mtb lpqN biofilms appear to
mature differently than WT Mtb biofilms potentially suggests
temporal modulation of LpqN function and is the focus of
ongoing investigation.
Recent work demonstrated that LpqN contributes to Mtb viru-
lence in a manner apart from its role in cell envelope biogenesis.
LpqN appears to interact with the host ubiquitin ligase Cbl
that down-regulates antibacterial immunity and potentiates
Mtb growth during ex vivo macrophage infection (39).
Although this capacity of LpqN to function as a virulence
factor is ostensibly unrelated to its apparent role in cell enve-
lope biogenesis, this finding underscores the critical impor-
Figure 2. Structures of the M. tuberculosis LpqN protein. A, representative section of electron density of apo-LpqN. The solvent-flattened electron density
(50 –1.65 Å) is contoured at 1.0  and superimposed with the final refined model (green, carbon; red, oxygen; blue, nitrogen). B, ribbon diagram of a protomer
of LpqN. The secondary structural elements of LpqN are colored green. C, surface representation of the electrostatic surface potentials of LpqN colored by
charge (red, negative 	15 kT/e; blue, positive 
15 kT/e). D, representative section of electron density of LpqN– 6LT. The solvent-flattened electron density
(50 –1.37 Å) is contoured at 1.0  and superimposed with the final refined model (orange, carbon; red, oxygen; blue, nitrogen). E, ribbon diagram of a protomer
of LpqN– 6LT. The secondary structural elements of LpqN are colored orange. The bound 6LT is in cyan. F, surface representation of the electrostatic surface
potentials of LpqN– 6LT colored by charge (red, negative 	15 kT/e; blue, positive 
15 kT/e). The bound 6LT is in cyan. A specific deep binding pocket, which was
not observed in apo-LpqN, was found to create on the LpqN– 6LT surface. G, representative section of electron density of LpqN–T6D. The solvent-flattened
electron density (50 –1.74 Å) is contoured at 1.0  and superimposed with the final refined model (sky blue, carbon; red, oxygen; blue, nitrogen). H, ribbon
diagram of a protomer of LpqN–T6D. The secondary structural elements of LpqN are colored sky blue. The bound T6D is in yellow. I, surface representation of
the electrostatic surface potentials of LpqN–T6D colored by charge (red, negative 	15 kT/e; blue, positive 
15 kT/e). The bound T6D is in yellow. A specific deep
binding pocket, which was not observed in apo-LpqN, was found to create on the LpqN–T6D surface.
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Figure 3. The LpqN ligand-binding site. A, the Fo 	 Fc simulated annealing electron density map of the bound 6LT within the LpqN protein. The bound 6LT
is shown as a stick model (cyan, carbon; red, oxygen). The simulated annealing Fo 	 Fc electron density map is contoured at 3.0  (gray mesh). B, the 2Fo 	 Fc
electron density map of the bound 6LT within the LpqN protein. The bound 6LT is shown as a stick model (cyan, carbon; red, oxygen). The 2Fo 	 Fc electron
density map is contoured at 1.0  (blue mesh). C, schematic representation of the LpqN and 6LT interactions. Amino acid residues within 3.5 Å from the bound
6LT are included. Dotted lines depict the hydrogen bonds. The hydrogen-bonded distances are also indicated in this figure. D, the Fo 	 Fc simulated annealing
electron density map of the bound T6D within the LpqN protein. The bound T6D is shown as a stick model (yellow, carbon; red, oxygen). The simulated
annealing Fo 	 Fc electron density map is contoured at 3.0  (gray mesh). E, the 2Fo 	 Fc electron density map of the bound T6D within the LpqN protein. The
bound T6D is shown as a stick model (yellow, carbon; red, oxygen). The 2Fo 	 Fc electron density map is contoured at 1.0  (blue mesh). F, schematic
representation of the LpqN and T6D interactions. Amino acid residues within 3.5 Å from the bound T6D are included. Dotted lines depict the hydrogen bonds.
The hydrogen-bonded distances are also indicated in this figure.
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tance of the mycobacterial cell envelope and its components
to pathogenesis.
Experimental procedures
Bacterial strains and growth conditions
The Mtb WT strain H37Rv was obtained from the ATCC.
Mycobacterial strains were routinely maintained in Middle-
brook 7H9 liquid medium (Difco) with 0.05% Tween 80 or on
Middlebrook 7H10 agar (Difco), both supplemented with albu-
min dextrose salts (ADSs) containing 8.1 mg/ml NaCl, 50
mg/ml BSA, and 20 mg/ml dextrose. Glycerol was added to
liquid 7H9 to a final concentration of 0.5%. Kanamycin (25
g/ml) and hygromycin (50 g/ml) were used to maintain bac-
terial selection when required.
The Mtb lpqN mutant was created via allelic exchange.
Upstream and downstream regions of lpqN homology were
amplified by PCR using lpqN 5/3 Forward/Reverse primers
(Table S2) and cloned to flank the hygromycin resistance gene
in pYUB854-rpsL (40). The resulting linear hygromycin prod-
uct flanked by regions of lpqN homology was amplified by PCR,
purified, concentrated, and used to transform electrocompe-
tent H37Rv/pJV53 (41). Transformants were selected on 7H10
agar containing ADS and hygromycin (75 g/ml). Individual
colonies were transferred to 7H10 agar containing hygromycin
(50 g/ml). Deletion of lpqN was confirmed via PCR using
flanking primers. Loss of the pJV53 recombineering plasmid
was accomplished through iterative culturing on 7H10 agar in
the absence of kanamycin and confirmed by susceptibility to
kanamycin (25 g/ml). For complementation, lpqN 
 1000-bp
upstream sequence was amplified via PCR with lpqN 	865/

1637 primers and cloned into the integrative vector pMV306
(42). The resulting complementation plasmid was transformed
into the Mtb lpqN mutant and transformants selected on 7H10
agar containing ADS and kanamycin (25 g/ml) and confirmed via
PCR (Fig. S1, A and B).
Mycobacterial biofilms were grown in Sauton’s medium con-
taining 0.5 g/liter K2HPO4, 0.5g/liter MgSO4, 4.0 g/liter L-as-
paragine, 0.05 g/liter ferric ammonium citrate, 4.76% glycerol,
and 1.0 mg/liter ZnSO4, with a final pH of 7.0. Mtb biofilms
were inoculated to A600  0.05 in Sauton’s medium and incu-
bated at 37 °C in 5% CO2 in tightly sealed polystyrene bottles. At
2 weeks, the lids were loosened to permit gas exchange.
Lipid isolation and analyses
Mtb lipids were harvested by collecting and centrifuging
planktonic or biofilm cultures in 50-ml conical vials, washing
once with PBS, and then moving to glass test tubes containing
3-mm glass beads. Surface lipids were extracted by shaking with
hexanes (5 ml) for 2 min, followed by pelleting (1000  g/10
min). Supernatants were removed into fresh glass tubes and
treated with HPLC-grade CHCl3:MeOH (2:1, v/v) prior to
removal from biosafety containment. For total lipid extraction,
bacterial pellets were autoclaved prior to removal from bio-
safety containment, then extracted with 5 ml of CHCl3:
MeOH (2:1, v/v) and 1 ml of HPLC-grade H2O by shaking and
bath sonication. The organic layer was separated by centrifuga-
tion (1000  g/10 min), transferred to preweighed vial, and
dried under inert N2 gas. mAGP was isolated as previously
described (43). Mycolic acid methyl esters (MAMEs) were
obtained by incubating mAGP in 15% tetrabutylammonium
hydroxide (overnight, 100 °C) followed by iodomethane (4 h,
room temperature) and extraction with dichloromethane.
Extracted lipids were resuspended in CHCl3 or dichlorometh-
ane (MAMEs) and loaded onto aluminum-backed silica plates
(EMD Millipore) for TLC analysis. Solvent systems used were
chloroform:methanol:ammonium hydroxide (80:20:2, v/v/v),
hexanes:ethyl acetate (99:5, v/v, three developments), and tolu-
ene:acetone (99:1, v/v) (Fisher). Lipids were visualized via
spraying with 12-molybdophosphoric acid (Alfa Aesar; 10%,
w/v in EtOH) and charring. The extracted lipids were also sub-
jected to LC/MS analysis using Agilent 6550A QTOF system in
conjunction with Agilent 1290 HPLC. HPLC separation and MS
data acquisition were performed as described previously (52).
Mycobacterial protein fragment complementation assay
The M-PFC screen was previously described and relies on
the reconstitution of two domains of the DHFR protein, which
confers resistance to trimethoprim (32). The MmpL3 and
MmpL11 D1 and D2 periplasmic domains were amplified by
PCR, and the products were subcloned into pGEM-T Easy
(Promega). Once confirmed by sequencing, the pUAB200 inte-
grative plasmids were constructed such that the D1 and D2
domains were in-frame with the DHFR [F3] fragment. The
pUAB200 was then transformed into M. smegmatis mc2155
generating bait strains. An H37Rv Mtb prey library of over 106
independent clones was generated in pUAB300. Briefly, H37Rv
genomic DNA was partially digested with HpaI, and fragments
between 0.5 and 2 kb were cloned into the ClaI site of pUAB300.
Library DNA was generated by a MaxiPrep (Qiagen). To screen
the library, electrocompetent bait strains were transformed
with the Mtb library DNA and plated to Kan25/Hyg50/Trim50
plates. Screens were considered successful if they resulted in
106 kanRhygR transformants. Clones that grew on trim-
ethoprim were screened by PCR to eliminate those that grew
because of the presence of pUAB300 plasmids containing the
Mtb dfrA (Rv2763c) gene. Sequencing of the prey Mtb genomic
library plasmid identified the genes fused to DHFR [F1,2]. The
MmpL11 D2–LpqN interaction was confirmed by direct clon-
ing of LpqN lacking its signal sequence into pUAB300 to gen-
erate in frame fusions with the DHFR [F1,2] fragment. The
MmpL D1 and D2–LpqN interactions were measured by deter-
mining the trimethoprim minimal inhibitory concentration.
Similarly, LpqT, LprG, and Mtc28 were cloned without their
signal sequences into pUAB300 to assess their interaction with
MmpL3/11 D2 domains. A pUAB300 plasmid containing the
Mtb dfrA (Rv2763c) gene was used as a positive control. Strains
were serially diluted onto 7H11 agar containing 2-fold dilutions
of trimethoprim from 6.25 to 200 g/ml.
Protein purification
The Escherichia coli LpqN expression construct was created
by amplifying lpqN lacking its signal sequence via PCR with
primers lpqN.61/687 followed by subcloning into pGEM-T
Easy. Upon sequence confirmation, the product was cloned
into pET-15b (Novagen) in frame with an N-terminal six-
histidine tag. This construct was transformed into E. coli
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BL21DE3, and protein production was induced at A600  0.5
with 0.4 mM IPTG (1 h/37 °C). Bacteria were harvested via
centrifugation and lysed via sonication. Protein was affinity-
purified over HisPur Cobalt Superflow agarose resin (Thermo)
and confirmed by Western blotting analysis.
LpqN–CFP pulldowns
Recombinantly expressed LpqN and CFPs (BEI Resources,
NR-14825, lot no. 610560541) (500 g each) were incubated
overnight at 4 °C in buffer A (300 mM NaCl, 50 mM NaPO4).
Cross-linking was performed using 1% formaldehyde for 30
min at room temperature, followed by quenching with 225 mM
glycine for 5 min. Cross-linked samples were buffer-exchanged
back into buffer A prior to LpqN purification on HisPur Cobalt
Superflow agarose resin (Thermo). LpqN from the non– cross-
linked sample was similarly purified. Background CFP binding
was assessed by flowing 500 g of CFP alone over the cobalt
resin. All resin-immobilized samples were washed (twice in
buffer A and once in buffer A 
 10 mM imidazole) and eluted in
buffer A 
 200 mM imidazole. LpqN-interacting proteins and
CFP background were identified by MS at the Oregon Health &
Science University Proteomics Shared Resource.
Protein mass spectrometry
0.5 ml of each eluate was concentrated and buffer-exchanged
with Amicon Ultra 3-kDa molecular mass cutoff filter. Samples
were solubilized in 0.05% ProteaseMAX, reduced with DTT,
alkylated with iodoacetamide, digested with trypsin overnight,
and dried. Each sample was dissolved in 20 l of 5% formic acid,
and 20 l/sample was injected into Orbitrap Fusion. Sample
digests were loaded onto an Acclaim PepMap 0.1  20 mm
NanoViper C18 peptide trap (Thermo Scientific) for 5 min at a
5 l/min flow rate in a 2% acetonitrile, 0.1% formic acid mobile
phase, and peptides separated using a PepMap RSLC C18,
2-m particle, 75-m  25-cm EasySpray column (Thermo
Scientific) using a 7.5–30% acetonitrile gradient over 60 min in
mobile phase containing 0.1% formic acid and a 300 nl/min flow
rate using a Dionex NCS-3500RS UltiMate RSLC nano UPLC
system. Tandem MS data were collected using an Orbitrap
Fusion Tribrid mass spectrometer configured with an EasyS-
pray NanoSource (Thermo Scientific). Survey scans were per-
formed in the Orbitrap mass analyzer at 120,000 resolution, and
data-dependent MS2 scans were performed in the linear ion
trap using higher-energy collisional dissociation following
isolation with the instrument’s quadrupole. Comet (version
2015.01, revision 1) was used to search MS2 Spectra against an
April 2017 version of the uniprot_Mycobacterium.tuberculosis_
h37rv_both.fasta (8352 entries) FASTA protein database, with
concatenated sequence-reversed entries to estimate error thresh-
olds and 179 common contaminant sequences and their reversed
forms (44). The database processing was performed with Python
scripts available at https://github.com/pwilmart/fasta_utilities.
git.3 Comet searches for all samples were performed with trypsin
enzyme specificity. The average parent ion mass tolerance was 2.5
Da. Monoisotopic fragment ion mass tolerance was 1.005 Da. A
static modification of 
57.02146 Da was added to all cysteine res-
idues. A variable modification of 
15.99491 Da on methionine
residues was also allowed.
LpqN expression and purification for crystallization studies
Briefly, the LpqN protein containing a His6 tag at the C ter-
minus was overproduced in E. coli BL21(DE3) cells possessing
pET15blpqN. The cells were grown in 2 liters of LB medium
with 100 g/ml ampicillin at 37 °C. When the A600 reached 0.5,
the culture was treated with 0.2 mM IPTG to induce LpqN
expression, and the cells were harvested within 3 h. The col-
lected bacterial cells were suspended in 100 ml of ice-cold
buffer containing 20 mM Na-HEPES (pH 7.2), 200 mM NaCl, 10
mM MgCl2, and 0.2 mg DNase I (Sigma–Aldrich). The cells
were then lysed with a French pressure cell. Cell debris was
removed by centrifugation for 45 min at 4 °C and 20,000 rpm.
The crude lysate was filtered through a 0.2-m membrane and
was loaded onto a 5-ml Hi-Trap Ni2
-chelating column (GE
Healthcare Biosciences, Pittsburgh, PA) pre-equilibrated with
20 mM Na-HEPES (pH 7.2) and 200 mM NaCl. To remove
unbound proteins and impurities, the column was first washed
with six column volumes of buffer containing 50 mM imidazole,
250 mM NaCl, and 20 mM Na-HEPES (pH 7.2). The LpqN pro-
tein was then eluted with four column volumes of buffer con-
taining 300 mM imidazole, 250 mM NaCl, and 20 mM Na-HEPES
(pH 7.2). The purity of the protein was judged using 12.5%
SDS-PAGE stained with Coomassie Brilliant Blue. The purified
protein was extensively dialyzed against buffer containing 20
mM Na-HEPES (pH 7.5), and concentrated to 15 mg/ml.
For the His6 selenomethionyl (SeMet)–substituted LpqN
protein expression, a 1-ml LB broth overnight culture contain-
ing E. coli BL21(DE3)/pET15blpqN cells was transferred into
20 ml of LB broth containing 100 g/ml ampicillin and grown at
37 °C. When the A600 value reached 1.2, the cells were harvested
by centrifugation at 3000  g/min for 10 min and then washed two
times with 10 ml of M9 minimal salt solution. The cells were resus-
pended in 20 ml of M9 medium and then transferred into a 2-liter
prewarmed M9 solution containing 100 g/ml ampicillin. The cell
culture was incubated at 37 °C with shaking. When the A600
reached 0.4, 100 mg/liter of lysine, phenylalanine, and threonine;
50 mg/liter isoleucine, leucine, and valine; and 60 mg/liter of L-sel-
enomethionine were added. The culture was continued to incu-
bate at 37 °C with shaking for 15 min. Protein expression was the
induced with 0.2 mM IPTG, and the cells were harvested within 3 h
after induction. The procedures for purifying His6 SeMet– LpqN
were identical to those of native LpqN.
Crystallization of LpqN
All crystals of the His6 LpqN protein were obtained using hang-
ing-drop vapor diffusion. The LpqN crystals were grown at room
temperature in 24-well plates with the following procedures. A
20-l protein solution containing 15 mg/ml LpqN protein in 20
mM Na-HEPES (pH 7.5) was mixed with a 2 l of reservoir solution
containing 0.1 M sodium citrate (pH 6.0) and 1.9 M (NH4)2SO4. The
resultant mixture was equilibrated against 500 l of the reservoir
solution. Crystals grew to a full size in the drops within 2 weeks.
Cryoprotection was achieved by raising the glycerol concentration
stepwise to 25% with a 5% increment in each step.
3 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
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Crystals of SeMet– LpqN were prepared using similar pro-
cedures. The reservoir solution for crystallizing SeMet– LpqN
is the same as that for native LpqN. These SeMet crystals grew
to a full size in the drops within 2 weeks. Cryoprotection was
achieved by raising the glycerol concentration stepwise to 25%
with a 5% increment in each step.
The LpqN– 6LT or LpqN–T6D crystals were prepare by
incubating the purified LpqN protein (15 mg/ml) with 0.1%
6LT or 0.1% T6D for 2 h at 4 °C before crystallization. Crystals
of LpqN– 6LT and LpqN–T6D were then prepared using sim-
ilar procedures as above. Their crystallization conditions are
identical to each other. The reservoir solution for these com-
plex crystals is the same as that for apo-LpqN (0.1 M sodium
citrate, pH 6.0, and 1.9 M (NH4)2SO4). Both crystals of LpqN–
6LT and LpqN–T6D grew to a full size in the drops within 2
weeks. Cryoprotection was achieved by raising the glycerol
concentration stepwise to 25% with a 5% increment in each
step.
Data collection, structural determination, and refinement
All diffraction data were collected at 100 K at Beamline
24ID-C located at the Advanced Photon Source, using a Pilatus
6M detector (Dectris Ltd.). Diffraction data were processed
using DENZO and scaled using SCALEPACK (45). Crystals of
LpqN, LpqN– 6LT, LpqN–T6D, and SeMet– LpqN belong to
space groups C121, I4, I4, and C121, respectively (Table 3).
The LpqN protein contains two methionines (excluding the
N-terminal methionine). Within the asymmetric unit of
SeMet– LpqN, these two selenium sites were identified using
SHELXC and SHELXD (46) as implemented in the HKL2MAP
package (47). Single anomalous dispersion was employed to
obtain experimental phases using the program Autosol (48) in
PHENIX (49). The resulting phases were then subjected to den-
sity modification and NCS averaging using the program PAR-
ROT (50) using the native structure factor amplitudes. The
SeMet sites were also used to trace the molecule by anomalous
difference Fourier maps, where we could ascertain the proper
registry of SeMet residues. The initial model of LpqN was con-
structed manually using program Coot (51). Then the model
was refined using PHENIX, leaving 5% of reflections in the
Free-R set. Iterations of refinement were performed using
PHENIX. Model buildings were done using Coot, which led to
the current model (Table 3).
The crystal structures of LpqN– 6LT and LpqN–T6D were
determined by molecular replacement, utilizing the final struc-
ture of LpqN as a search model. The procedures for structural
refinement and model building were the same as those of LpqN
(Table 3).
LpqN–MmpL11/Ag85A interaction
HA-tagged LpqN was amplified by PCR using lpqN 	570.F/

HA.R primers and the resulting product cloned into the
pOLYG plasmid to generate pOLYG lpqN HA where LpqN is
expressed from its native promoter. MmpL11 was amplified
using mmpL11 TAP.F/R primers and ligated in-frame with the
tandem affinity-tagged (TAP; His6 and FLAG tag) tag into
pOLYG-TAP plasmid to generate pOLYG mmpL11-TAP plas-
mid. MmpL11 expression in the pOLYG mmpL11 TAP is
driven by its native promoter. The lpqN-HA fragment was
ligated into the pOLYGmmpL11–TAP plasmid to generate the
pOLYGlpqN–HA/mmpL11–TAP co-expression plasmid. HIS-
tagged Ag85A was amplified using Ag85A.F/R primers and
ligated into the pOLYG plasmid via NEBuilder (New England
Biolabs) to generate pOLYGag85A-HIS. The lpqN HA frag-
ment was ligated into the pOLYGag85a-HIS plasmid to gener-
ate the pOLYGlpqN-HA/ag85A-HIS co-expression plasmid, as
above. To test the LpqN/MmpL11 interaction, M. smegmatis
mc2155 was transformed with either pOLYGlpqN-HA or
pOLYGlpqN-HA/mmpL11-TAP, and grown in 7H9 liquid
medium, as above. Protein cross-linking was induced by adding
formaldehyde to a final concentration of 1% for 30 min at room
temperature. All samples were quenched with 2.5 M glycine,
washed with 1 PBS, and lysed in urea lysis buffer (8 M urea, 300
mM NaCl, 0.5% Nonidet P-40, 50 mM NaH2PO4, 50 mM Tris,
Roche Complete protease inhibitor, pH 7.0) via sonication. The
lysates were incubated on buffer-equilibrated HisPur Cobalt
Superflow agarose resin (Thermo Scientific), washed extensively,
and eluted in urea lysis buffer adjusted to 300 mM imidazole. Resin
flow through and elutions were separated via SDS-PAGE (10%)
and analyzed by Western blotting (1:2500 mouse monoclonal
-FLAG/-HA; Thermo Scientific). To test the LpqN/Ag85A
interaction, M. smegmatis was transformed with pOLYGag85a–
His or pOLYGlpqN–HA/ag85A–HIS and cross-linked as above.
Washed cell pellets were lysed in 1 PBS 
 Roche Complete pro-
tease inhibitor via sonication and incubated on Pierce HA epitope
tag antibody agarose conjugate (Thermo Scientific). Resin-bound
proteins were extensively washed in lysis buffer, eluted in 50 mM
NaOH, and immediately quenched with 1.0 M Tris, pH 8.5.
Lysates, resin flow-through, and elutions were separated via SDS-
PAGE (15%) and analyzed by Western blotting (1:1000 rabbit
polyclonal -HIS/-HA; Thermo Scientific).
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